Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

CEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in forced vital capacity (FVC) between baseline and Week 52.  The trial is planned to enroll approximately 500 IPF patients with mild-to-moderate impairment in lung function and certain characteristics that the company believes enhance the probability of a successful study outcome.

Third Quarter and First Nine Months 2012 Financial Results (Unaudited)
InterMune reported total revenue in the third quarter of 2012 of $7.5 million, compared with $0.1 million in the third quarter of 2011.  Third quarter 2012 revenue included $0.5 million of favorable adjustments to revenue primarily related to favorable foreign exchange fluctuations.  InterMune reported total revenue for the first nine months of 2012 of $18.0 million, compared with $2.7 million in the first nine months of 2011.  Revenue was almost entirely from sales of Esbriet in Germany, as active promotion in the largest of the mid-sized countries for which pricing and reimbursement is approved began in September of 2012.  Included in the third quarter 2012 results was the effect of the approximate 11 percent German price decrease of Esbriet, which became effective on September 15, 2012 as previously announced.  Total revenue in the first nine months of 2011 included $2.6 million of revenue from the company's research collaboration with Roche, which was completed in June 2011.Research and development (R&D) expenses in the third quarter of 2012 were $26.2 million, compared with $17.0 million in the third quarter of 2011, an increase of 54 percent.  R&D expenses were $74.6 million for the nine months ended September 30, 2012, compared with $54.0 million in the same period of 2011, an increase of 38 percent.  Higher R&D expenses in both the three- and nine-month periods of 2012, compared with the same periods in 2011, reflect expenses related to conduc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune To Release Third Quarter Financial Results On November 7
2. InterMune To Present At JMP Securities Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune to Present at J. P. Morgan Healthcare Conference
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
8. Patient Safety Technologies Reports Third Quarter 2012 Results
9. PDI Reports 2012 Third Quarter Financial Results
10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... (NASDAQ: SQNM ), a life sciences company ... new publication from the large Women & Infants multi-center ... (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) ... Prenatal Diagnosis . Along with this week,s publication, the ...
... May 16, 2012  Sigma-Aldrich announced today that it has ... will mature on May 10, 2017.  The new facility ... scheduled to mature on December 11, 2012.  The $600 ... paper program and be used for general corporate purposes. ...
... Reportlinker.com announces that a new market research ...   Global Anti-Microbial Coatings ...   This report analyzes the US ... the following End-Use Segments: Indoor Air Quality, and ...
Cached Biology Technology:Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 2Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 3Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 4Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 5Global Anti-Microbial Coatings Industry 2Global Anti-Microbial Coatings Industry 3Global Anti-Microbial Coatings Industry 4Global Anti-Microbial Coatings Industry 5Global Anti-Microbial Coatings Industry 6Global Anti-Microbial Coatings Industry 7Global Anti-Microbial Coatings Industry 8Global Anti-Microbial Coatings Industry 9Global Anti-Microbial Coatings Industry 10Global Anti-Microbial Coatings Industry 11Global Anti-Microbial Coatings Industry 12Global Anti-Microbial Coatings Industry 13
(Date:4/17/2014)... stem cell therapies to cure a variety of diseases ... based on cell surface markers. Researchers from the Finnish ... highly expressed in a type of stem cells derived ... an article in BioResearch Open Access , a ... article is available free on the BioResearch ...
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... congenital valvular heart disease. Now, in patients with this ... the Netherlands, the University of Newcastle, UK and the ... identified mutations in a gene which plays an important ... hope that these findings will lead to faster diagnosis ...
... Jan. 10, 2011 Aware, Inc. (Nasdaq: AWRE ... telecommunications and biometrics industries, today announced that on January 5, ... Jr. and John S. Stafford, III to the Aware Board ... a Class III Director and will serve on the Board,s ...
... Bio-Technology Group Co., Inc. (OTC Bulletin Board: ... leading developer, manufacturer and marketer of Traditional Chinese ... other health and nutritional products in the People,s ... its private placement offering for aggregate gross proceeds ...
Cached Biology News:Researchers link gene mutations to Ebstein's anomaly 2Aware Announces Appointment of New Directors 2Aware Announces Appointment of New Directors 3Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3
... a powerful technology platform that automates gel ... High quality sample preparation can be carried ... Xcise is a powerful technology platform that ... analysis. It combines the functions of high-resolution ...
Request Info...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... is a new generation bulk reagent dispenser ... simplicity for pharmaceutical and biotech laboratories. Based ... range, Multidrop Combi has been designed for ... 0.5-2500 l and multiple plate types including ...
Biology Products: